对此，康霖生物科技杭州有限公司创始人吴昊泉也深有体会。去年年底，该企业完成了A轮融资， 总金额1.5亿元，其中钱塘产业基金投资1亿元。目前，由康霖生物自主研发的产品KL003细胞注射液， 已经成功治愈数十例地中海贫血症患者，且治疗成本远低于国际竞品。此外，钱塘还帮助企业对接银 行、担保机构，成功争取到专精特新担保贷800万元。 在钱塘新一轮产业基金矩阵中，主导子基金由专注投资钱塘优势主导产业的7只非定向基金和助力 重大项目招引的6只定向基金组成，实现"车药芯化航"全主导产业全生命周期全覆盖。此外，基金阵容 还包括管理子基金和合作子基金。去年，区内企业天镜生物寻求资产重组，管理子基金主动帮助企业与 投资机构开展10余轮对接，最终帮助企业完成超5亿元人民币的C1轮融资，实现资产整合重组。在融资 助力下，该企业发展势头良好，生长激素管线与菲泽妥单抗已提交上市申请，尤莱利单抗与赛诺菲达成 战略合作，另有多个重点管线快速推进中。接下来，钱塘产业基金将继续聚焦硬科技、坚持长周期、提 高容错率，通过市场化方式帮助区内企业快速发展。 作为产业大区，钱塘（新）区本周落地新一轮产业基金矩阵：钱塘和达产业基金，该产业基金按 照"母 ...

Core Viewpoint - Heng Rui Pharmaceutical's recent IPO in Hong Kong marks a significant step towards internationalization, raising approximately 9.89 billion HKD, making it the largest domestic pharmaceutical IPO of the year [3][4]. Group 1: Company Overview - Heng Rui Pharmaceutical has been a leader in China's innovative drug sector, with a strong focus on international operations through licensing agreements, contributing significantly to its revenue [3][4]. - The company has completed 14 licensing agreements for innovative drugs, with 9 of these occurring in the last three years, indicating a rapid acceleration in its international expansion efforts [3][10]. Group 2: Market Challenges - The implementation of national drug procurement policies since 2016 has significantly impacted Heng Rui's revenue, particularly affecting its generics business, which accounted for 82% of its revenue in 2019 [8][9]. - The average price drop for drugs that entered procurement has exceeded 50%, leading to substantial revenue declines for Heng Rui, which saw its revenue peak at 27.735 billion CNY in 2020 before experiencing consecutive declines [9][16]. Group 3: Strategic Transformation - In response to market pressures, Heng Rui has shifted its focus towards innovative drugs, with the proportion of innovative drug revenue rising to 46.6% in 2023, surpassing 10 billion CNY for the first time [10][24]. - The company has significantly reduced its generics R&D projects, focusing instead on innovative drugs, with 57 clinical approvals for innovative drugs compared to only 1 for generics in 2024 [24][25]. Group 4: Financial Performance - Heng Rui's revenue dropped by 6.59% in 2021, marking its first decline post-IPO, largely due to the impact of procurement policies [16][18]. - The company's net profit increased by 32.98% in 2024, attributed to recognizing a 1.6 billion EUR upfront payment from Merck for licensing agreements [59]. Group 5: Internationalization Strategy - Heng Rui's internationalization strategy includes various approaches such as direct licensing and joint development with foreign companies, aiming to enhance its global market presence [57][58]. - The company has engaged in several business development (BD) transactions, including a notable partnership with Merck, which could yield significant future revenues [59][60]. Group 6: Competitive Landscape - The competitive landscape for innovative drugs is intensifying, with rivals like BeiGene achieving significant sales milestones, highlighting the need for Heng Rui to innovate and differentiate its product offerings [28][31]. - Heng Rui's leading product, the PD-1 inhibitor, has faced pricing pressures due to increased competition, necessitating ongoing investment in marketing and physician education to maintain market share [35][36].

Core Viewpoint - Heng Rui Medicine has successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 98.9 billion, marking the largest pharmaceutical IPO in China this year. This move is seen as a significant step towards internationalization for the company [2]. Group 1: Company Overview - Heng Rui Medicine is recognized as a leading company in China's innovative drug sector, with a strong pipeline of products. The company has primarily relied on licensing agreements for international expansion, with 14 licensing deals completed, 9 of which occurred in the last three years [2][3]. - The company has not engaged in any financing activities since its A-share IPO in 2000, making this recent listing a notable event in its history [3]. Group 2: Impact of Policy Changes - The implementation of national drug procurement policies since 2016 has significantly impacted Heng Rui's operations, particularly affecting its revenue from generic drugs, which constituted 82% of its income in 2019 [7][8]. - The average price drop for drugs that have undergone procurement has exceeded 50%, creating substantial pressure on the company's profitability [7][21]. Group 3: Financial Performance - Following a peak revenue of CNY 27.735 billion in 2020, Heng Rui's income has declined for two consecutive years due to procurement policies, but it began to stabilize in 2023 [8]. - The company's revenue from innovative drugs has increased to 46.6% of total revenue in 2023, surpassing CNY 10 billion for the first time [8][27]. Group 4: Strategic Transformation - Heng Rui has shifted its focus from generic drugs to innovative drug development, significantly reducing its generic drug projects and increasing its innovative drug pipeline [27][29]. - The company has established research centers globally to monitor trends and gather patent information, although it lacks a standout blockbuster product [36]. Group 5: International Expansion Strategies - Heng Rui's international strategy includes three main approaches: self-expansion, direct licensing, and joint ventures. The company has increasingly opted for direct licensing to reduce costs and risks [57][65]. - Recent licensing agreements have generated significant upfront payments, such as a EUR 160 million deal with Merck, contributing to a 32.98% increase in net profit in 2024 [66]. Group 6: Challenges and Future Outlook - The company faces challenges in the competitive landscape of innovative drugs, particularly in the PD-1 market, where it must navigate pricing pressures and market acceptance [40][43]. - Heng Rui's recent foray into NewCo transactions, which involve complex asset and equity financing, indicates a strategic pivot towards leveraging external capital for growth [68][69].